China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...

They have at least one thing in common: An exciting pipeline.

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the ...

Vedana Therapeutics emerged from stealth with a $46M Series A.

Veraxa Biotech (VRXA) rated Sell: shares look overvalued post‑SPAC. The pipeline’s fragility is pronounced. See here for more ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

Kardigan Inc. shares surged 38% in its trading debut, after the heart-health focused biotech raised $400 million in an ...

By Leila Miller BUENOS AIRES, June 19 (Reuters) - Argentina's government has repealed a regulation that had restricted ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...